Tag Archives: Emerging Companies

Save Money! Register Now for BIO Investor Forum – Early Bird Deadline is Wed, Aug 31

Don’t miss the opportunity to register early and get a discounted rate for the 2016 BIO Investor Forum. Held at the Westin St. Francis Hotel in San Francisco Oct. 18-19, this conference explores investment trends and opportunities in life sciences and focuses on venture-stage growth and emerging public companies. The registration price will increase after the August 31st deadline. With an impressive array of company presentations, panel discussions on industry trends, thought-provoking fireside chats and Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,

BIO Applauds House Passage of the Fostering Innovation Act

scientist, lab

The House of Representatives has overwhelmingly passed the Fostering Innovation Act (H.R. 4139), a key capital markets priority for BIO. The bipartisan legislation was introduced by Reps. Kyrsten Sinema (D-AZ) and Michael Fitzpatrick (R-PA). The JOBS Act provides emerging growth companies (EGCs) with a five-year exemption from Section 404(b) of Sarbanes-Oxley (SOX), which requires a costly external attestation of a company’s internal financial controls. The Fostering Innovation Act would extend the JOBS Act’s SOX 404(b) Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

BIO Welcomes Seven New Board Members

new-bio-logo

BIO elected seven new members to its Board of Directors, voted upon at this year’s Board Meetings, held this week in New York City. The following individuals were elected to the Health Section Governing Board: Christopher Boerner, President and Head of the U.S. Commercial Business, BMS Mark Alles, President and Chief Operating Officer, Celgene Gary Zieziula, President and Managing Director, EMD Serono Elizabeth Lewis, Chief Counsel and Chief Compliance Officer, Takeda Pharmaceuticals Jean-Christophe Tellier, Chief Read More >

Corporate  |  Leave a comment  |  Email This Post
Tags: , ,

Tick Size Pilot Program: A Few Pennies Make a Big Difference

72263479

Earlier this week, the Securities and Exchange Commission (SEC) approved a tick size pilot program that will begin next year. We issued this statement, praising the SEC for finalizing this program, which could improve liquidity and enhance capital formation for emerging biotech companies. Under current SEC rules, all securities on the public market are priced in $0.01 increments known as “tick sizes.” The switch to the standard tick size of a penny was enacted in 2000 Read More >

Business and Investments, Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Members of Congress Agree: Reg A+ Rules Need National Standard

Biotech IPOs Infographic

We’ve written before about the importance of implementing Title IV of the JOBS Act (commonly referred to as the “Reg A+” provision) in a way that will best encourage biotech capital formation. BIO President and CEO Jim Greenwood also discussed the issue in an op-ed at Forbes last week. At issue is whether the SEC will set a national standard for the review of Reg A+ offerings or instead subject companies to the labyrinth that Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , ,